如果 Covid 疫苗成为年度事件,阿斯利康,人造卫星疫苗将面临障碍

The Straits Times · 2021-02-26
ZURICH (REUTERS) - Vaccines from AstraZeneca , Russia's Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual inoculations become necessary to fight new variants ... That potentially puts vector vaccines at a disadvantage to mRNA shots from Pfizer and Moderna, or vaccines using deactivated coronaviruses, like Sinovac's, or the coronavirus' surface spike proteins, an approach pursued by Novavax ... Vector immunity is not a new issue but has come under renewed scrutiny as companies including J&J anticipate regular Covid-19 vaccinations, like annual influenza shots, may be needed to combat new variants of the coronavirus.
讨论